Xenetic Biosciences, Inc. (XBIO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of XBIO were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No XBIO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
XBIO short interest
Low short interest. 1.6% of XBIO shares are sold short: about 1 share in 63. Over the last 12 reports the number of shares short went up 526%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 37,018 XBIO shares were sold short, 1.6% of the shares outstanding, up 237.7% from the report before. At the average daily volume of 31,416 shares, buying them all back would take about 1.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 37,018 | 1.58% | +238% | 31,416 | 1.2 |
| Oct 15, 2026 | 10,961 | 0.47% | -15% | 20,326 | 1.0 |
| Sep 30, 2026 | 12,868 | 0.55% | -43% | 277,145 | 1.0 |
| Sep 15, 2026 | 22,465 | 0.96% | +11% | 50,468 | 1.0 |
| Aug 31, 2026 | 20,320 | 0.87% | -55% | 31,148 | 1.0 |
| Aug 14, 2026 | 45,169 | 1.93% | +299% | 111,557 | 1.0 |
| Jul 31, 2026 | 11,313 | 0.48% | -41% | 16,846 | 1.0 |
| Jul 15, 2026 | 19,290 | 0.84% | -18% | 16,355 | 1.2 |
| Jun 30, 2026 | 23,589 | 1.03% | +158% | 19,757 | 1.2 |
| Jun 15, 2026 | 9,143 | 0.40% | -44% | 19,697 | 1.0 |
| May 29, 2026 | 16,388 | 0.72% | +177% | 8,366 | 2.0 |
| May 15, 2026 | 5,914 | 0.26% | -19% | 14,613 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Xenetic Biosciences company events
Xenetic Biosciences filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 23, 2026.
- Sep 23, 2026AnnouncementShared information with investors. Filing
- Sep 16, 2026AgreementXenetic Biosciences, Inc., a Nevada corporation, entered into a Share Exchange Agreement with Santersus AG, a Swiss corporation ( Aktiengesellschaft ), the sellers listed on Schedule I thereto (each, a “Seller,” and collectively with the holders of Santersus securities who subsequently become… Filing
- Aug 7, 2026ResultsReleased financial results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 24, 2026LeadershipThe Compensation Committee of the Board of Directors of Xenetic Biosciences, Inc. approved a grant under the Xenetic Biosciences, Inc. Amended and Restated Equity Incentive Plan (as amended from time to time, the “Plan”), to James Parslow, the Company’s Interim Chief Executive Officer and Chief… Filing
- Mar 13, 2026ResultsReleased financial results. Filing
- Jan 9, 2026AnnouncementXenetic Biosciences, Inc. announced that its 2025 Annual Meeting of Stockholders, originally scheduled for December 11, 2025, had been adjourned until January 8, 2026 in order to achieve a quorum and allow additional time to solicit proxies on behalf of the Company’s board of directors. Filing
- Dec 11, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Xenetic Biosciences financials
Famous investors that hold XBIO
2 of the 50 well-known investors we track reported holding XBIO in their latest 13F filing. The largest position is Jim Simons's, worth $128K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 55,040 | $128K | 0.0% | -53% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 15,346 | $35.6K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named XBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Renaissance Technologies LLC | 13G/A | 2.4% |
| Nov 12, 2026 | Renaissance Technologies LLC | 13G/A | 2.4% |
Questions about Xenetic Biosciences, Inc. (XBIO) stock
Are XBIO insiders buying or selling?
No XBIO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in XBIO?
As of Oct 30, 2026, 37,018 XBIO shares were sold short, 1.6% of the shares outstanding, up 237.7% from the report before. At the average daily volume of 31,416 shares, buying them all back would take about 1.2 trading days (days to cover). See the history.
Which famous investors hold XBIO?
2 of the 50 well-known investors we track reported XBIO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $128K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.